Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.2.1.36 (hyaluronidase)
 4,606 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A new human rhabdomyosarcoma cell strain, designated KYM-1, has been established from a neck tumor found in a 9-month-old infant. The cultured cells were round and mainly free-floating or in a moniliform pattern with a population doubling time of 75 hours. In stained preparations, the cells were pleomorphic and had a single round or oval nucleus in non-striated cytoplasm. However, the intracellular presence of myogenic markers was clearly shown by enzyme-immunochemical stains. An ultrastructural feature of the KYM-1 cells was the presence of numerous intermediate filaments in the perinuclear area and around the Golgi complexes which were associated with abundant cell organelles and aggregates of glycogen granules. High viscosity of the spent culture medium was attributed to hyaluronic acid, identified by electrophoresis and hyaluronidase digestion, and immunological and biochemical analyses revealed that the increased concentration of plasminogen activator activity found in the culture medium was almost wholly of the tissue plasminogen activator type. The KYM-1 cells also contained high concentrations of alkaline phosphatase activity. Tumorigenicity of the cells was confirmed by heterotransplantation into hamsters treated with anti-thymocyte serum.
 ...
PMID:Characterization of a human rhabdomyosarcoma cell strain in tissue culture. 383 Feb 65

The aim of using enzymes in vitreoretinal surgery is to facility PVD and create pharmacological vitrectomy. It can be achieved by liquefying the gel structure of the vitreous (synchisis) and weakening of adherence of the posterior vitreous cortex to retina (syneresis). The article reviews currently used enzymes in vitreoretinal surgery (plasmin, hyaluronidase, dispase, chondroitinase, collagenase, urokinase, TPA--tissue plasminogen activator) and presents potential profits and side-effects related to their use. Although the day when vitreous surgery is replaced by pharmacological vitreolisis remains still as a future, these enzymes hold great promise. Additionally it has been proved that enzymes can be used successfully as an intraoperative adjuvant in vitrectomy.
 ...
PMID:[Use of enzyme in vitreoretinal surgery]. 1204 13

Various pharmacologic vitreolysis agents, including hyaluronidase, urea, plasmin, dispase, tissue plasminogen activator and chondroitinase have been tested. Pharmacologic vitreolysis can avoid the complications of surgery such as cataract, endophthalmitis, retinal hemorrhage, tear or detachment, and anesthesia related complications. Hyaluronan is a major macromolecule of vitreous. It is a long, unbranched polymer of repeating disaccharide (glucuronic acid beta (1,3)-N-acetylglucosamine) moieties linked by beta 1-4 bonds. Hyaluronan is covalently linked to a protein core, to form a proteoglycan. It plays a pivotal role in stabilizing the vitreous gel. Hyaluronidase cleaves glycosidic bonds of hyaluronic acid and, to a variable degree, other acid mucopolysaccharides of the connective tissue. Dissolution of the hyaluronic acid and collagen complex results in decreased viscosity of the extracellular matrix. This in turn increases the diffusion rate of erythrocytes and exudates along with phagocytes through the vitreous and facilitates red blood cell lysis and phagocytosis.
 ...
PMID:Hyaluronidase for pharmacologic vitreolysis. 1949 48